Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.5.1787

Updated Meta-analysis of the TP53 Arg72Pro Polymorphism and Gastric Cancer Risk  

Xiang, Bin (Department of Gastroenterology, the Affiliated Jiangyin Hospital of Southeast University Medical School)
Mi, Yuan-Yuan (The Third Affiliated Hospital of Nantong University)
Li, Teng-Fei (Department of Gastroenterology, the Affiliated Jiangyin Hospital of Southeast University Medical School)
Liu, Peng-Fei (Department of Gastroenterology, the Affiliated Jiangyin Hospital of Southeast University Medical School)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.5, 2012 , pp. 1787-1791 More about this Journal
Abstract
Objective: The p53 tumor suppressor pathway plays an important role in gastric cancer (GC) development. Auto-regulatory feedback control of p53 expression is critical to maintaining proper tumor suppressor function. So far, several studies between p53 Arg72Pro polymorphism and GC have generated controversial and inconclusive results. Methods: To better assess the purported relationship, we performed a meta-analysis of 19 publications. Eligible studies were identified by searching the Pubmed database. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess any link. Results: Overall, a significant association was detected between the p53 Arg72Pro polymorphism and GC risk (Pro-allele vs. Arg-allele: OR = 1.05, 95%CI = 1.01-1.08; Pro/Pro vs. Arg/Arg: OR = 1.13, 95%CI = 1.04-1.22). Moreover, on stratified analysis by race, significantly increased risk was found for Asian populations (Pro-allele vs. Arg-allele: OR = 1.06, 95%CI = 1.02-1.10; Pro/Pro vs. Arg/Arg: OR = 1.16, 95%CI = 1.07-1.26; Pro/Pro+Pro/Arg vs. Arg/Arg: OR = 1.58, 95%CI = 1.09-2.27). Conclusions: Our study provided evidence that the p53 72Pro allele may increase GC risk in Asians. Future studies with larger sample size are warranted to further confirm this association in more detail.
Keywords
P53; gastric cancer; polymorphism; meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bergamaschi D, Gasco M, Hiller L, et al (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402.   DOI   ScienceOn
2 Birgander R, Sjalander A, Zhou Z, et al (1996). p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered, 46, 49-54.   DOI
3 Capella G, Pera G, Sala N, et al (2008). DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol, 37, 1316-25.   DOI
4 De Feo E, Persiani R, La Greca A, et al (2009). A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res, 675, 60-5.   DOI   ScienceOn
5 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI
6 Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI
7 Etienne MC, Chazal M, Laurent-Puig P, et al (2002). Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol, 20, 2832-43.   DOI   ScienceOn
8 Gao L, Nieters A, Brenner H (2009). Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet, 17, 1658-67.   DOI   ScienceOn
9 Gomes de Souza L, Miranda de Lima J, Dale Cotrim Guerreiro da Silva I, Manoukian Forones N (2009). P53 Arg72Pro polymorphism in gastric cancer patients. J Gastrointest Cancer, 40, 41-5.   DOI
10 Hamajima N, Matsuo K, Suzuki T, et al (2002). No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett, 181, 81-5.   DOI
11 Hiyama T, Tanaka S, Kitadai Y, et al (2002). p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer, 100, 304-8.   DOI   ScienceOn
12 Ihsan R, Devi TR, Yadav DS, et al (2011). Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol, 30, 163-71.   DOI   ScienceOn
13 Lai KC, Chen WC, Tsai FJ, Li SY, Jeng LB (2005). Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology, 52, 944-8.
14 Katkoori VR, Jia X, Shanmugam C, et al (2009). Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res, 15, 2406-16.   DOI   ScienceOn
15 Ke-Xiang Z, Yu-Min L, Xun L, et al (2012). Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China. Mol Biol Rep, 39, 723-8.   DOI
16 Kim N, Cho SI, Lee HS, et al (2010). The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci, 55, 101-10.   DOI
17 Lane DP (1992). Cancer. p53, guardian of the genome. Nature, 358, 15-6.   DOI   ScienceOn
18 Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31.   DOI   ScienceOn
19 Li Y, Prives C (2007). Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene, 26, 2220-5.   DOI
20 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
21 Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A (2010). p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer, 47, 31-4.   DOI   ScienceOn
22 Mu LN, Lu QY, Yu SZ, et al (2005). Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer, 116, 972-83.   DOI
23 Shen H, Solari A, Wang X, et al (2004). P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep, 11, 1115-20.
24 Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3, 389-92.   DOI   ScienceOn
25 Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.   DOI   ScienceOn
26 Perez-Perez GI, Bosques-Padilla FJ, Crosatti ML, Tijerina-Menchaca R, Garza-Gonzalez E (2005). Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol, 40, 56-60.   DOI
27 Shepherd T, Tolbert D, Benedetti J, et al (2002). Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology, 118, 1039-44.
28 Shirai O, Ohmiya N, Taguchi A, et al (2010). P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology, 57, 1595-601.
29 Sjalander A, Birgander R, Hallmans G, et al (1997). p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17, 1313-6.
30 Song HR, Kweon SS, Kim HN, et al (2011). p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer, 14, 242-8.   DOI
31 Sul J, Yu GP, Lu QY, et al (2006). P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett, 238, 210-23.   DOI   ScienceOn
32 Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.   DOI
33 Vogelstein B, Lane D, Levine AJ (2002). Surfing the p53 network. Nature, 408, 307-10.
34 Wu MT, Chen MC, Wu DC (2004). Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett, 205, 61-8.   DOI   ScienceOn
35 Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol, 8, 275-83.   DOI
36 Walker KK, Levine AJ (1996). Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA, 93, 15335-40.   DOI   ScienceOn
37 Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999). Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer, 35, 226-30.   DOI   ScienceOn
38 Xi YG, Ding KY, Su XL, et al (2004). p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis, 25, 2201-6.   DOI   ScienceOn
39 Yi SY, Lee WJ (2006). A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol, 12, 6536-9.   DOI
40 Zhang ZW, Newcomb P, Hollowood A, et al (2003). Ageassociated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res, 9, 2151-6.
41 Zhang ZW, Newcomb P, Hollowood A, et al (2004). A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. Dig Dis Sci, 49, 254-9.   DOI
42 Zhou Y, Li N, Zhuang W, et al (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer, 121, 1481-6.   DOI   ScienceOn